Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.48 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.48 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6190824 | 1.00 | CYP2D6 (0.49) | CYP2D6CYP2C9CYP2C19RECQLSMN1; SMN2 | |
| SCHEMBL6193353 | 1.00 | CYP2D6 (0.49) | CYP2D6CYP2C9CYP2C19RECQLSMN1; SMN2 | |
| SCHEMBL6194780 | 1.00 | CYP2D6 (0.49) | CYP2D6CYP2C9CYP2C19RECQLSMN1; SMN2 | |
| SCHEMBL6193349 | 1.00 | CYP2D6 (0.49) | CYP2D6CYP2C9CYP2C19RECQLSMN1; SMN2 | |
| SCHEMBL6190821 | 1.00 | CYP2D6 (0.49) | CYP2D6CYP2C9CYP2C19RECQLSMN1; SMN2 | |
| SCHEMBL7173228 | 0.96 | ITGB1 (0.48) | CYP2D6CYP2C9CYP2C19RECQLSMN1; SMN2 | |
| SCHEMBL6751575 | 0.85 | TACR1 (0.51) | CYP2D6CYP2C9CYP2C19RECQLALDH1A1 | |
| SCHEMBL6370800 | 0.85 | TACR1 (0.51) | CYP2D6CYP2C9CYP2C19RECQLALDH1A1 | |
| SCHEMBL27462559 | 0.85 | TACR1 (0.51) | CYP2D6CYP2C9CYP2C19RECQLALDH1A1 | |
| SCHEMBL25453255 | 0.84 | CYP2D6 (0.52) | CYP2D6CYP2C9CYP2C19RECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628965-B1 | HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS | WILEX AG (DE) | 2015-07-22 | — | — | EP | disclosed |
| EP-2248901-A1 | Streptogramines and method for preparing same by mutasynthesis | Aventis Pharma S.A. (FR) | 2010-11-10 | — | — | EP | disclosed |
| EP-2243774-A1 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | Wilex AG (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-7807681-B2 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | WILEX AG (DE) | 2010-10-05 | — | — | US | disclosed |
| EP-0770132-B1 | NEW STREPTOGRAMINES | AVENTIS PHARMA SA (FR) | 2010-09-08 | — | — | EP | disclosed |
| US-20100068272-A1 | HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS | WILEX AG (DE) | 2010-03-18 | — | — | US | disclosed |
| US-7608623-B2 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | WILEX AG (DE) | 2009-10-27 | — | — | US | disclosed |
| EP-1511721-B1 | GUANIDINO PHENYLALANIN COMPOUNDS USED AS UROKINASE INHIBITORS | WILEX AG (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-7538216-B2 | Guanidino phenylalanin compounds used as urokinase inhibitors | WILEX AG (DE) | 2009-05-26 | — | — | US | disclosed |
| US-20080261998-A1 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | WILEX AG (DE) | 2008-10-23 | — | — | US | disclosed |
| EP-1299365-A1 | 2-AMINOTHIAZOLINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | Aventis Pharma S.A. (FR) | 2003-04-09 | — | — | EP | disclosed |
| US-20020198243-A1 | 2-aminothiazoline derivatives and process for preparing the same | CARRY JEAN-CHRISTOPHE (FR) | 2002-12-26 | — | — | US | disclosed |
| US-20020187987-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | CARRY JEAN-CHRISTOPHE (FR) | 2002-12-12 | — | — | US | disclosed |
| US-6451821-B1 | ADMINISTERING TO A PATIENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF 2-AMINOTHIAZOLINE DERIVATIVES FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH AN ABNORMAL PRODUCTION OF NITRIC OXIDE(NO) | AVENTIS PHARMA S.A. (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | AVENTIS PHARMA S.A. (FR) | 2002-02-21 | — | — | US | disclosed |
| CN-1330076-A | Endothelin antagon | INST OF TOXIC MEDICINES PLA S (CN) | 2002-01-09 | — | — | CN | disclosed |
| CN-1330077-A | Endothelin antegon | INST OF TOXIC MEDICINES PLA S (CN) | 2002-01-09 | — | — | CN | disclosed |
| WO-2001094325-A1 | 2-AMINOTHIAZOLINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2001-12-13 | — | — | WO | disclosed |
| EP-0770132-A1 | STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | Aventis Pharma S.A. (FR) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996001901-A1 | STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | RHONE-POULENC RORER S.A. (FR) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068272-A1 | HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS | PLAU, PLAUR, HPN | CYP2D6 1619/4885CYP2C9 1257/4885CYP2C19 1728/4885 |
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | NOS2, NOS3, NOS1 | CYP2D6 68/4885CYP2C9 98/4885CYP2C19 170/4885 |
| US-20020198243-A1 | 2-aminothiazoline derivatives and process for preparing the same | NOS3, TH, CBR1 | CYP2D6 47/4885CYP2C9 55/4885CYP2C19 102/4885 |
| US-20080261998-A1 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | PLAU, PLAUR, HPN | CYP2D6 1619/4885CYP2C9 1257/4885CYP2C19 1728/4885 |
| US-20020187987-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | NOS2, NOS3, NOS1 | CYP2D6 79/4885CYP2C9 98/4885CYP2C19 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.